Urofollitropin - Uses And Benefits

Type of Drug:

Gonadotropin; hormone that stimulates the ovaries.

How the Urofollitropin Products Works:

Sitmulates eggs in the ovaries to fully develop before ovulation.

Uses of the Urofollitropin:

Used with human chorionic gonadotropin (HCG) to induce ovulation.

Urofollitropin and HCG may be used to stimulate the development of multiple eggs in patients participating in assisted reproductive programs.

Before therapy: Women must have a thorough pelvic exam and testing of the endocrine glands. A cervical dilation and curettage (D and C) must he done before beginning therapy if there is abnormal uterine bleeding or other signs of endometriosis. The partner's fertility potential must also ho evaluated by a doctor.

Ovarian enlargement: Mild to moderate uncomplicated ovarian enlargement, which may be accompanied by abdominal bloating or pain, occurs in approximately 20% of patients treated with urofollitropin and HCG. It usually regresses without treatment within 2 to 3 weeks. If significant ovarian enlargement occurs after ovulation, do not engage in sexual intercourse.

Pregnancy: Do not use during pregnancy. The risk of use in a pregnant women clearly outweighs any possible benefit.

Breastfeeding: It is not known if urofollitropin is excreted in breast milk. Consult your doctor before you begin breastfeeding.

Children: Not indicated for use in children.

Lab Tests: Lab tests may be required to monitor therapy. Tests include estradiol laves and ultrasongraphy.

Side Effects of The Urofollitropin:

Every drug is capable of producing side effects. Many patients experience no, or minor, side effects. The frequency and severity of side effects depend on many factors including dose, duration of therapy, and individual susceptibility. Possible side effects include:

Digestive Tract: Nausea; vomiting; diarrhea; stomach cramps.

Urinary and Reproductive Tract: Bloating; severe pelvic pain; bleeding into the pelvic area (hemoperitoneum); ovarian hyper stimulation syndrome (OHSS); vaginal bleeding; ovarian enlargement; ovarian cysts.

Skin: Rash, pain, swelling, or irritation at injection site; dry skin; hair loss; hives; itching; facial swelling.

Other: Headache; breast tenderness; pain; multiple births; hot flashes; enlarged abdomen; intra vascular thrombosis and embolism (blood clots in the legs or lungs, lung damage, stroke, death).

Guidelines for Use:

Dosage is individualized. Use exactlyasprE3scribed.

Do not stop taking or change the dose, unless instructed by.your doctor.

Inject Bravelle subcutaneously(SC;beneath the skin) or intramuscularly' leally (lM; into a muscle).inject Fertile SC.

Visually inspect solution for discoloration or particles. Use immediately after reconstitution (mixing). Discard any unused portion.

If a dose is missed, inject it as soon as possible. If several hours have passed or it is nearing time for the next dose, do not double the dose to catch up, unless instructed by your doctor. If more than one dose is missed or it is necessary to establish a new dosage schedule, contact your doctor or pharmacist.

Discontinue use and contact your doctor immediately severe pelvic pain, bloating, nausea, vomiting, diarrhea, faculty breathing, or decreased urination.

BeG must be given following urofollitropin when tests follicles are present (eg, changes in vaginal smear or cervicalnary estrogen test) .

Qvulation is confirmed by testing for progesterone itlbasal temperature, change in cervical mucus).

A couple should have intercourse daily, beginning on the day prior to HCG administration, until ovulation occurs. Take care to ensure insemination. However, intercourse should be prohibited in patients in whom significant ovarian enlargement occurs after ovulation.

Monitor for signs of pregnancy. If pregnancy is suspected, contact your doctor.

Multiple. pregnancy is possible and poses potential hazards.

Lab tests may be required to monitor therapy. Be sure to keep appointments.

Store refrigerated or $t room temperature (30. to 77 F). light.